he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Subscribe To Our Newsletter & Stay Updated
